Nitto Denko Corporation (Headquarters: Osaka; President, CEO & COO: Hideo Takasaki; hereafter “Nitto”) held a company information meeting for institutional investors and analysts on May 13th, 2016.
During the meeting, CEO Hideo Takasaki reported on results for the previous fiscal year, and explained Nitto's current business plan as well as its mid-term management plan, which covers the next three years. He then answered questions on topics of particular interest to institutional investors and analysts, such as his outlook on each business and the areas that Nitto intends to focus on in the future. Due to increasing interest related to the development of fibrosis treatments that use molecular targeted drug delivery systems, Kageshi Maruyama (Senior Vice President & Executive Manager of Business Development) joined Mr. Takasaki during the second half of the meeting to explain the status of treatment development and give his forecast for the future.

You can see the digest version of the company information meeting below.
Company Information Meeting

Overview of Mid-term Management Plan
Nitto’s mid-term management is a rolling plan that is revised every year. Nitto-2018, the recently released mid-term management plan, covers the three-year period from the 2016 fiscal year until the company's 100th anniversary in 2018. Nitto-2018 will serve as a bridge to the company's 100th anniversary and, going forward, the Nitto-New Century. Nitto intends to continue to strengthen its efforts in developing new businesses in the Green (environment), Clean (new energy), and Fine (life sciences) domains; promoting continuous reform as it puts business portfolio reform into high gear; and maintaining a balanced growth.